Company Highlights - Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has experienced a 76.53% increase in its stock price, reaching $4.62, attributed to progress in its drug pipeline, particularly the Phase 1b trial for ATI-052 targeting atopic dermatitis [1][5] - Corvus Pharmaceuticals, Inc. (CRVS) has seen a remarkable 142.73% increase, with its stock price hitting $19.54, driven by promising results in its eczema treatment and a focus on immuno-oncology therapies, especially its lead product candidate, Mupadolimab [2][5] - RAPT Therapeutics, Inc. (RAPT) saw its stock price increase by 63.83% to $57.50, despite an investigation into potential breaches of fiduciary duty, with investor interest driven by promising drug candidates like RPT193 and FLX475 [3] Market Overview - Recent market movements highlight the dynamic nature of the stock market, with companies across different sectors experiencing rapid changes in valuations [4]